Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Palatin Technologies (PTN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Palatin Technologies, Inc....

GEO : 22.48 (-1.40%)
QTNA : 14.86 (+0.34%)
NAVG : 69.51 (unch)
IVR : 15.73 (+0.64%)
PTN : 0.72 (-1.37%)
RVNC : 19.91 (-3.82%)
Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic...

PTN : 0.72 (-1.37%)
Palatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need...

PTN : 0.72 (-1.37%)
Earnings Preview: Palatin (PTN) Q1 Earnings Expected to Decline

Palatin (PTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTN : 0.72 (-1.37%)
Recent Analysis Shows Booz Allen Hamilton Holding, j2 Global, Leidos, The Hain Celestial Group, Palatin Technologies, and Marsh & McLennan Companies Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Booz Allen Hamilton Holding...

MMC : 83.00 (-1.23%)
JCOM : 70.78 (-1.13%)
BAH : 49.12 (-2.48%)
PTN : 0.72 (-1.37%)
LDOS : 57.05 (-2.38%)
HAIN : 18.45 (-3.91%)
Immunotherapy Market Value Grows as the Treatments Gains Widespread Importance

According to a report published by Progressive Markets, the cancer immunotherapy market was valued at USD 57.2 Billion in 2017 and is expected to reach USD 166.7 Billion by 2025 while growing at a compound...

AGEN : 2.42 (-3.20%)
RGBP : 0.0031 (-8.82%)
ZIOP : 2.84 (-2.41%)
PTN : 0.72 (-1.37%)
BLRX : 0.62 (-3.12%)
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic...

PTN : 0.72 (-1.37%)
AMAG : 16.80 (-1.12%)
Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018

Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2018 operating results on Thursday, September 13, 2018 before the open of the U.S. financial markets....

PTN : 0.72 (-1.37%)
Global Biotechnology Market Grows as Demand for Immunotherapy Cancer Treatment Increases

Data compiled by Grand View Research indicates that the global biotechnology market is expected to reach USD 727.1 Billion by 2025. The technological advancement of regenerative therapies is one of the...

RGBP : 0.0031 (-8.82%)
ADMP : 2.81 (-2.77%)
NVAX : 2.41 (+4.78%)
PTN : 0.72 (-1.37%)
SGYP : 0.08 (-38.46%)
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need...

PTN : 0.72 (-1.37%)
Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2018 operating results on Tuesday, May 15, 2018 before the open of the U.S. financial markets.

PTN : 0.72 (-1.37%)
Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery Communications, Vertex Pharmaceuticals, The New York Times, Palatin Technologies, and E*TRADE Financial -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American Homes 4 Rent (NYSE:AMH),...

DISCK : 26.02 (+0.12%)
VRTX : 170.06 (-1.94%)
NYT : 24.49 (-1.96%)
PTN : 0.72 (-1.37%)
AMH : 20.62 (+0.19%)
ETFC : 43.55 (-1.60%)
Palatin Technologies Presents Positive Preclinical MC1 Receptor Agonist Data at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs...

PTN : 0.72 (-1.37%)
Pre-Market Technical Scan on Healthcare Equities -- Atossa Genetics, Palatin Technologies, Quotient, and Avadel Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ATOS, PTN, QTNT, and AVDL which can be accessed for free by signing up to www.wallstequities.com/registration....

AVDL : 2.45 (-9.26%)
ATOS : 1.23 (+3.36%)
PTN : 0.72 (-1.37%)
QTNT : 7.20 (-3.36%)
Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need...

PTN : 0.72 (-1.37%)
AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide, which AMAG in-licensed from...

PTN : 0.72 (-1.37%)
AMAG : 16.80 (-1.12%)
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs...

PTN : 0.72 (-1.37%)
AMAG : 16.80 (-1.12%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA -11.08
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures ended the Friday session with most contracts steady to 1/2 cent higher, as Dec expired at $3.76 3/4. USDA reported a private export sale of 125,000 MT of corn to Japan this morning. Corn export commitments through December 6 were 16.3% l...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar